Treatment with sodium-glucose cotransporter 2 inhibitors reportedly leads to reduced liver fat content [44] and has been associated with a lower risk of major hepatic events in type 2 diabetes mellitus [45]. Here, SLC5A2 is linked to type 2 diabetes mellitus.